Amgen (AMGN) Change in Intangibles (2014 - 2015)
Amgen's quarterly Change in Intangibles came in at $5.0 million in Q3 2015, down 96.3% quarter-over-quarter from $135.0 million in Q4 2014.
Amgen has reported Change in Intangibles for 2 years, with the latest figure at $5.0 million in Q3 2015.
- For the quarter ending Q3 2015, Change in Intangibles changed N/A year-over-year to $5.0 million; the trailing twelve-month figure through Dec 2015 stood at $140.0 million (changed N/A YoY), and the FY2016 full-year result was $99.0 million, up 80.0% from the prior year.
- Change in Intangibles for Q3 2015 stood at $5.0 million, down from $135.0 million in the prior quarter.
- The five-year high for Change in Intangibles was $135.0 million in Q4 2014, with the low at $5.0 million in Q3 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | -461.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 5.00 Mn |
| Sep 30, 2015 | 5.00 Mn |
| Dec 31, 2014 | 135.00 Mn |
| Dec 31, 2014 | 135.00 Mn |